» Articles » PMID: 23386904

Cystatins in Immune System

Overview
Journal J Cancer
Specialty Oncology
Date 2013 Feb 7
PMID 23386904
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Cystatins comprise a large superfamily of related proteins with diverse biological activities. They were initially characterised as inhibitors of lysosomal cysteine proteases, however, in recent years some alternative functions for cystatins have been proposed. Cystatins possessing inhibitory function are members of three families, family I (stefins), family II (cystatins) and family III (kininogens). Stefin A is often linked to neoplastic changes in epithelium while another family I cystatin, stefin B is supposed to have a specific role in neuredegenerative diseases. Cystatin C, a typical type II cystatin, is expressed in a variety of human tissues and cells. On the other hand, expression of other type II cystatins is more specific. Cystatin F is an endo/lysosome targeted protease inhibitor, selectively expressed in immune cells, suggesting its role in processes related to immune response. Our recent work points on its role in regulation of dendritic cell maturation and in natural killer cells functional inactivation that may enhance tumor survival. Cystatin E/M expression is mainly restricted to the epithelia of the skin which emphasizes its prominent role in cutaneous biology. Here, we review the current knowledge on type I (stefins A and B) and type II cystatins (cystatins C, F and E/M) in pathologies, with particular emphasis on their suppressive vs. promotional function in the tumorigenesis and metastasis. We proposed that an imbalance between cathepsins and cystatins may attenuate immune cell functions and facilitate tumor cell invasion.

Citing Articles

Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption.

Gai D, Caviness P, Lazarenko O, Chen J, Randolph C, Zhang Z Cancers (Basel). 2025; 17(5).

PMID: 40075680 PMC: 11899016. DOI: 10.3390/cancers17050833.


Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera.

Hickey T, Mudunuri U, Hempel H, Kemp T, Roche N, Talsania K Front Immunol. 2025; 15:1502458.

PMID: 39931577 PMC: 11808009. DOI: 10.3389/fimmu.2024.1502458.


Preoperative Serum Cystatin C as an Independent Prognostic Factor for Survival in Patients with Renal Cell Carcinoma.

Ma H, Wang P, Hou Z, Zhou H, Lv D, Cui F J Cancer. 2024; 15(18):5978-5985.

PMID: 39440052 PMC: 11493004. DOI: 10.7150/jca.97711.


Urinary cystatin-C and urinary NGAL associated with sepsis predicts longer hospital stay in premature newborns.

Silva Barbosa J, Meneses G, Castelo L, da Silva Junior G, Martins A, Daher E Biomark Med. 2024; 18(15-16):649-658.

PMID: 39263780 PMC: 11404570. DOI: 10.1080/17520363.2024.2377532.


Molecular characterization, expression and immune functional analysis of cystatin 10 in turbot.

Zhang F, Duan Z, Chen Q, Wang X, Li H, Tao Z Mol Biol Rep. 2024; 51(1):709.

PMID: 38824265 DOI: 10.1007/s11033-024-09634-y.


References
1.
Cheng T, Hitomi K, van Vlijmen-Willems I, de Jongh G, Yamamoto K, Nishi K . Cystatin M/E is a high affinity inhibitor of cathepsin V and cathepsin L by a reactive site that is distinct from the legumain-binding site. A novel clue for the role of cystatin M/E in epidermal cornification. J Biol Chem. 2006; 281(23):15893-9. DOI: 10.1074/jbc.M600694200. View

2.
Rivenbark A, Jones W, Coleman W . DNA methylation-dependent silencing of CST6 in human breast cancer cell lines. Lab Invest. 2006; 86(12):1233-42. DOI: 10.1038/labinvest.3700485. View

3.
Lalioti M, Mirotsou M, Buresi C, Peitsch M, Rossier C, Ouazzani R . Identification of mutations in cystatin B, the gene responsible for the Unverricht-Lundborg type of progressive myoclonus epilepsy (EPM1). Am J Hum Genet. 1997; 60(2):342-51. PMC: 1712389. View

4.
Berdowska I . Cysteine proteases as disease markers. Clin Chim Acta. 2004; 342(1-2):41-69. DOI: 10.1016/j.cccn.2003.12.016. View

5.
Cox J, Sexton P, Green T, Darmani N . Inhibition of B16 melanoma metastasis by overexpression of the cysteine proteinase inhibitor cystatin C. Melanoma Res. 1999; 9(4):369-74. DOI: 10.1097/00008390-199908000-00005. View